Analysts Anticipate OncoSec Medical Inc (ONCS) Will Announce Earnings of -$0.23 Per Share
Brokerages expect OncoSec Medical Inc (NASDAQ:ONCS) to report ($0.23) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for OncoSec Medical’s earnings. OncoSec Medical reported earnings per share of ($0.29) during the same quarter last year, which would suggest a positive year over year growth rate of 20.7%. The firm is scheduled to announce its next earnings report on Thursday, January 18th.
According to Zacks, analysts expect that OncoSec Medical will report full year earnings of ($0.86) per share for the current year. For the next year, analysts expect that the firm will post earnings of ($0.71) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow OncoSec Medical.
OncoSec Medical (NASDAQ:ONCS) last announced its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported ($0.28) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by ($0.05).
Shares of OncoSec Medical (ONCS) traded down $0.06 during midday trading on Friday, hitting $1.94. The company had a trading volume of 358,977 shares, compared to its average volume of 738,917. The company has a market cap of $68.90, a PE ratio of -1.88 and a beta of 3.27. OncoSec Medical has a 1-year low of $0.88 and a 1-year high of $2.95.
WARNING: This article was first posted by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was stolen and reposted in violation of US & international copyright and trademark laws. The original version of this article can be accessed at https://www.americanbankingnews.com/2018/01/14/analysts-anticipate-oncosec-medical-inc-oncs-will-announce-earnings-of-0-23-per-share.html.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.